Literature DB >> 10443882

Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13.

P L Kramer1, M Mineta, C Klein, K Schilling, D de Leon, M R Farlow, X O Breakefield, S B Bressman, W B Dobyns, L J Ozelius, A Brashear.   

Abstract

Rapid-onset dystonia-parkinsonism (RPD) is an autosomal dominant movement disorder characterized by sudden onset of persistent dystonia and parkinsonism, generally during adolescence or early adulthood. Symptoms evolve over hours or days, and generally stabilize within a few weeks, with slow or no progression. Other features include little or no response to L-dopa, and low levels of homovanillic acid in the central nervous system. Neuroimaging studies indicate no degeneration of dopaminergic nerve terminals in RDP, suggesting that this disorder results from a functional deficit, as in dystonia, rather than neuronal loss, as in Parkinson's disease. We studied 81 members of two midwestern US families with RDP, 16 of whom exhibited classic features of RDP. We found significant evidence for linkage in these two families to markers on chromosome 19q13, with the highest multipoint LOD score at D19S198 (z = 5.77 at theta = 0.0). The flanking markers D19S587 and D19S900 define a candidate region of approximately 8 cM. Although RDP itself is a rare condition, it is important because it has clinical and biochemical similarities to both Parkinson's disease and dystonia. Identification of the genetic defect in RDP holds promise for understanding the underlying disease processes of both of these more common diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10443882     DOI: 10.1002/1531-8249(199908)46:2<176::aid-ana6>3.0.co;2-2

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  13 in total

Review 1.  Using the shared genetics of dystonia and ataxia to unravel their pathogenesis.

Authors:  Esther A R Nibbeling; Cathérine C S Delnooz; Tom J de Koning; Richard J Sinke; Hyder A Jinnah; Marina A J Tijssen; Dineke S Verbeek
Journal:  Neurosci Biobehav Rev       Date:  2017-01-28       Impact factor: 8.989

Review 2.  Primary dystonia: molecules and mechanisms.

Authors:  Lauren M Tanabe; Connie E Kim; Noga Alagem; William T Dauer
Journal:  Nat Rev Neurol       Date:  2009-10-13       Impact factor: 42.937

3.  Auditory-perceptual voice and speech evaluation in ATP1A3 positive patients.

Authors:  Mary E Moya-Mendez; Lyndsay L Madden; Kathryn W Ruckart; Karen M Downes; Jared F Cook; Beverly M Snively; Allison Brashear; Ihtsham U Haq
Journal:  J Clin Neurosci       Date:  2020-10-05       Impact factor: 1.961

Review 4.  The aetiology of idiopathic Parkinson's disease.

Authors:  D B Ramsden; R B Parsons; S L Ho; R H Waring
Journal:  Mol Pathol       Date:  2001-12

5.  Genome sequencing identifies a novel mutation in ATP1A3 in a family with dystonia in females only.

Authors:  Robert Wilcox; Ingrid Brænne; Norbert Brüggemann; Susen Winkler; Karin Wiegers; Lars Bertram; Tim Anderson; Katja Lohmann
Journal:  J Neurol       Date:  2014-10-31       Impact factor: 4.849

Review 6.  Cervical dystonia pathophysiology and treatment options.

Authors:  M Velickovic; R Benabou; M F Brin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Mutations in THAP1 (DYT6) in early-onset dystonia: a genetic screening study.

Authors:  Susan B Bressman; Deborah Raymond; Tania Fuchs; Gary A Heiman; Laurie J Ozelius; Rachel Saunders-Pullman
Journal:  Lancet Neurol       Date:  2009-04-01       Impact factor: 44.182

Review 8.  Primary dystonia: moribund or viable.

Authors:  Susan B Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

Review 9.  Distinct neurological disorders with ATP1A3 mutations.

Authors:  Erin L Heinzen; Alexis Arzimanoglou; Allison Brashear; Steven J Clapcote; Fiorella Gurrieri; David B Goldstein; Sigurður H Jóhannesson; Mohamad A Mikati; Brian Neville; Sophie Nicole; Laurie J Ozelius; Hanne Poulsen; Tsveta Schyns; Kathleen J Sweadner; Arn van den Maagdenberg; Bente Vilsen
Journal:  Lancet Neurol       Date:  2014-05       Impact factor: 44.182

10.  A novel recurrent mutation in ATP1A3 causes CAPOS syndrome.

Authors:  Michelle K Demos; Clara Dm van Karnebeek; Colin Jd Ross; Shelin Adam; Yaoqing Shen; Shing Hei Zhan; Casper Shyr; Gabriella Horvath; Mohnish Suri; Alan Fryer; Steven Jm Jones; Jan M Friedman
Journal:  Orphanet J Rare Dis       Date:  2014-01-28       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.